The drug used in the treatment of diabetes was authorized by Anvisa to be used in people who have obesity. The National Health Surveillance Agency (Anvisa) approved the product this Monday, 2. The medicine, capable of reducing people's weight, has already been released in Brazil.
see more
China: Undisputed leader in electric vehicles – How they…
Should I share the soap with my family?
This is the name of the medicine that was released by Anvisa. the drug Semaglutide has 2.4 mg and is indicated for individuals who are overweight and comorbidities.
Wegovy, from Novo Nordisk pharmaceuticals, was authorized only for the treatment of people who were affected with type 2 diabetes. Despite the dosage being 1 mg, it was found that the tests showed a reduction in body weight of up to 17% in 68 weeks.
According to the pharmaceutical company, the treatment is done with weekly injections and has contributed to a 20% reduction in body weight in one out of three people. 83.5% of the patients showed a decrease in weight equal to or greater than 5%.
The side effects are: gastrointestinal alterations, such as nausea, diarrhea, vomiting, coldand abdominal pain.
The drug belongs to a class of drugs that is within the range of scientists. For them, the medicine can become a very powerful weapon in the fight against obesity.
Substances act on hormone receptors developed by the intestine, such as GLP-1. It is connected to appetite control and reducing the rate of emptying of the stomach, making you feel fuller for longer.
The Food and Drug Administration (FDA), the US regulatory agency, approved, in 2021, the treatment for individuals who were obese or overweight and who had at least some type of comorbidity.
Some countries, such as the United States and Japan, have already allowed the drug to be used, with a dosage that favors weight loss. Although the medicine has been approved, there is still no date for the launch of the medicine in Brazil.
Everything needs to be fixed for this to happen. In addition, other procedures, such as the price of the medicine, must be defined by the Medicines Market Regulation Chamber.